Selling, General, and Administrative Costs: United Therapeutics Corporation vs Summit Therapeutics Inc.

SG&A Expenses: United vs. Summit Therapeutics (2014-2023)

__timestampSummit Therapeutics Inc.United Therapeutics Corporation
Wednesday, January 1, 20146795238381287000
Thursday, January 1, 20157454247452612000
Friday, January 1, 201610345862316800000
Sunday, January 1, 201716984203330100000
Monday, January 1, 201816187290265800000
Tuesday, January 1, 20199299233.54336200000
Wednesday, January 1, 202019232000423900000
Friday, January 1, 202123611000467000000
Saturday, January 1, 202226700000487000000
Sunday, January 1, 202328215000477100000
Loading chart...

In pursuit of knowledge

A Tale of Two Therapeutics: SG&A Expenses Over Time

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This chart compares the SG&A expenses of United Therapeutics Corporation and Summit Therapeutics Inc. from 2014 to 2023. United Therapeutics consistently outpaces Summit Therapeutics, with expenses peaking at nearly 500% higher in 2022. Notably, United Therapeutics' SG&A expenses reached their zenith in 2022, while Summit Therapeutics saw a steady increase, culminating in a 315% rise over the decade. This trend highlights United Therapeutics' expansive operational scale compared to Summit Therapeutics' more conservative growth. As the industry evolves, these financial strategies will play a pivotal role in shaping each company's future trajectory.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025